STOCK TITAN

Immunocore (IMCR) director granted 27,492 share options as award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Immunocore Holdings plc director John Irving Bell received a grant of 27,492 share options. Each option gives the right to buy one ordinary share at an exercise price of $28.52 and expires on May 26, 2036. According to the terms, the options vest at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting, provided he remains in continuous service until that vesting date. Following this award, he holds 27,492 derivative securities linked to ordinary shares.

Positive

  • None.

Negative

  • None.
Insider Bell John Irving
Role null
Type Security Shares Price Value
Grant/Award Share Option (Right to Buy) 27,492 $0.00 --
Holdings After Transaction: Share Option (Right to Buy) — 27,492 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 27,492 options Share Option (Right to Buy) granted to director
Exercise price $28.52 per share Conversion or exercise price of options
Expiration date May 26, 2036 Option grant expiration
Underlying shares 27,492 ordinary shares Underlying security shares for the options
Post-transaction derivative holdings 27,492 options Total derivative securities following grant
Vesting date condition Earlier of May 27, 2027 or day before next AGM Subject to continuous service through vesting date
Share Option (Right to Buy) financial
"security_title: "Share Option (Right to Buy)""
Ordinary Shares financial
"underlying_security_title: "Ordinary Shares""
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
exercise price financial
"conversion_or_exercise_price: "28.5200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-05-26T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest financial
"The shares subject to the option award shall vest at the earlier of"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual general meeting financial
"the day immediately prior to the date of the Issuer's next annual general meeting"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bell John Irving

(Last)(First)(Middle)
C/O IMMUNOCORE HOLDINGS PLC
92 PARK DRIVE, MILTON PARK

(Street)
ABINGDONOXFORDSHIREOX14 4RY

(City)(State)(Zip)

UNITED KINGDOM

(Country)
2. Issuer Name and Ticker or Trading Symbol
Immunocore Holdings plc [ IMCR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (Right to Buy)$28.5205/27/2026A27,492 (1)05/26/2036Ordinary Shares27,492$027,492D
Explanation of Responses:
1. The shares subject to the option award shall vest at the earlier of (i) May 27, 2027 and (ii) the day immediately prior to the date of the Issuer's next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.
/s/ Lily Hepworth, Attorney-in-Fact05/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Immunocore (IMCR) report for John Irving Bell?

Immunocore reported that director John Irving Bell received a grant of 27,492 share options. These options are a compensation award, not an open-market purchase, and give him the right to buy ordinary shares at a fixed exercise price if they vest.

What are the key terms of John Irving Bell’s new options at Immunocore (IMCR)?

John Irving Bell was granted 27,492 share options with an exercise price of $28.52 per ordinary share, expiring May 26, 2036. The options vest only if he continues serving the company through the specified vesting date conditions outlined in the grant.

When do John Irving Bell’s Immunocore (IMCR) options vest?

The options vest at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting. Vesting is conditional on his continuous service with the company through that date, meaning unvested options could be forfeited if service ends earlier.

Is John Irving Bell’s Immunocore (IMCR) Form 4 transaction a market purchase or sale?

The Form 4 shows a grant of share options as compensation, not a market trade. The transaction is coded as an acquisition of derivatives, with no cash purchase or share sale in the market, so it does not directly reflect open-market trading sentiment.

How many shares could John Irving Bell acquire from his new Immunocore (IMCR) options?

If fully vested and exercised, the 27,492 options allow John Irving Bell to acquire 27,492 ordinary shares. He would need to pay the $28.52 exercise price per share to convert these options into actual shares after meeting the vesting conditions.